Clinical Trial Update: Efficacy and Safety of Increased Dose of TA-650 (Infliximab) in Patients With Crohn's Disease (CD) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating higher-dose TA-650 (Infliximab) for Crohn's disease, reporting efficacy and safety results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• TA-650 (Infliximab) (Infliximab)

Snippet

Sponsor: Tanabe Pharma Corporation | Conditions: Crohn's Disease | Phase 3 | Status: COMPLETED | Results posted: 2012-12-05